Participant flow

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant · Source last updated 2018-09-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.

   id

   FG000

   title

   Arm A

2. description

   Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.

   id

   FG001

   title

   Arm B

3. description

   Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.

   id

   FG002

   title

   Arm C

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         1

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         1

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice